NCT01637636 - Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Healthy

Interventions

DRUG

tasimelteon

20mg, oral capsule, once, Days 1 and 12

DRUG

tasimelteon

20mg, oral capsule, once, Days 1 and 6

DRUG

Rifampin

600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11

DRUG

Ketoconazole

400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6

Trial Locations (1)

QPS Bio-Kinetic Clinical Applications, Springfield